Not Just Bulk Drugs, This Segment Too Is Doing Well For Divi’s Laboratories
A capsule is arranged for a photograph (Photographer: Kiyoshi Ota/Bloomberg)

Not Just Bulk Drugs, This Segment Too Is Doing Well For Divi’s Laboratories

Indian pharmaceutical companies saw their businesses grow in the pandemic-marred first quarter, mostly aided by bulk drugs amid global supply chain disruptions and trade pushback against China. But...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.